Its also approved for the prevention of cardiac events such as heart attack and stroke
The mechanisms responsible for the reduced risk of adverse CV events with GLP-1RAs may be related to inhibition of the progression of atherosclerotic lesions by multiple pathways, primarily involving reduced inflammatory processes within the atherosclerotic plaque
High obesity prevalence, increasing physician adoption of GLP-1 therapies, and broad patient acceptance of injectable self-administration are supporting market growth
ORCID: Affiliation: 8 Neuroscience Theme, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney NSW 2006, Australia 9 Laboratory of Neurobiology and Pathological Physiology, Institute of Animal Physiology and Genetics, Academy of Sciences of the Czech Republic, 602 00 Brno, Czech Republic These authors contributed equally to this work